WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130459
CAS#: 2242952-69-6
Description: BMS-986299 is an agonist of the nucleotide-binding domain and leucine-rich repeat-containing protein 3 (NLRP3). By activating NLRP3, BMS-986299 leads to NLRP3 inflammasome-mediated secretion of interleukin-8 (IL-8), which may promote anti-tumor activity of natural killer cells, potentially providing an alternate pathway in the treatment of certain cancers.
Hodoodo Cat#: H130459
Name: BMS-986299
CAS#: 2242952-69-6
Chemical Formula: C18H19N7O
Exact Mass: 349.17
Molecular Weight: 349.400
Elemental Analysis: Chemical Formula: Exact Mass: Molecular Weight: Elemental Analysis: C, 61.88; H, 5.48; N, 28.06; O, 4.58
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BMS-986299; BMS986299; BMS 986299
IUPAC/Chemical Name: N-((4-amino-7-(1H-pyrazol-5-yl)-3H-imidazo[4,5-c]quinolin-2-yl)methyl)-N-ethylacetamide
InChi Key: UHNRLQRZRNKOKU-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H19N7O/c1-3-25(10(2)26)9-15-22-16-12-5-4-11(13-6-7-20-24-13)8-14(12)21-18(19)17(16)23-15/h4-8H,3,9H2,1-2H3,(H2,19,21)(H,20,24)(H,22,23)
SMILES Code: CC(N(CC(N1)=NC2=C1C(N)=NC3=CC(C4=CC=NN4)=CC=C23)CC)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 349.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Bi C, Chadwick J, Davies ML, DelMonte AJ, Geng P, Glace AW, Green RA, Gurak JA Jr, Haley MW, He BL, Inankur B, Jamison CR, Joe CL, Kolotuchin S, Lin D, Lou S, Nye J, Ortiz A, Purdum GE, Rosso VW, Shah M, Simmons EM, Stevens JM, Strotman NA, Tan Y, Zhang L. Coupling-Condensation Strategy for the Convergent Synthesis of an Imidazole-Fused 2-Aminoquinoline NLRP3 Agonist. J Org Chem. 2023 Jan 6;88(1):384-394. doi: 10.1021/acs.joc.2c02395. Epub 2022 Dec 14. PMID: 36516991.
2. https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2017-1041.html
3. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nlrp3-agonist-bms-986299